901 related articles for article (PubMed ID: 26461476)
1. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
2. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
4. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
7. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
[TBL] [Abstract][Full Text] [Related]
8. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
10. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.
Camorani S; Esposito CL; Rienzo A; Catuogno S; Iaboni M; Condorelli G; de Franciscis V; Cerchia L
Mol Ther; 2014 Apr; 22(4):828-41. PubMed ID: 24566984
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
[TBL] [Abstract][Full Text] [Related]
13. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
14. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
16. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
[TBL] [Abstract][Full Text] [Related]
17. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
Newman JP; Wang GY; Arima K; Guan SP; Waters MR; Cavenee WK; Pan E; Aliwarga E; Chong ST; Kok CYL; Endaya BB; Habib AA; Horibe T; Ng WH; Ho IAW; Hui KM; Kordula T; Lam PYP
Nat Commun; 2017 Dec; 8(1):1913. PubMed ID: 29203859
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
20. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
